1. Delivering clinical research to make patients, and the NHS, better Breast SSG Sept 2015 Research Duncan Wheatley Clinical and Sub Specialty Research Lead Wendy Cook, Research Delivery Manager dd/mm/yyyy

2. Breast Tumour Group National Perspective Data from Portfolio ODP – Cut off 21/08/15

3. Breast Tumour Group National Perspective LCRN 2014/20152015/2016 CommercialNon-CommercialTotalRankCommercialNon-CommercialTotalRank East Midlands398008393 991100 8 Eastern106356457 8210218 4 Greater Manchester18493149491 10512522 1 Kent, Surrey and Sussex1831833611 992101 7 North East and North Cumbria518519014 43741 14 North Thames254404659 90 12 North West Coast538739210 88997 9 North West London136927056 3270273 2 South London76112812042 35209244 3 South West Peninsula3828732512 207494 10 Thames Valley and South Midlands69910515 43539 15 Wessex55375428 39194 10 West Midlands327667984 9148157 6 West of England1227128313 67278 13 Yorkshire and Humber347557895 12157169 5 Data from Portfolio ODP – Cut off 21/08/15

4. Breast Tumour Group Open Studies East Midlands Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes12 An exploratory breast lead interval study (EBLIS)15783Non-CommercialObservationalNo7 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo226 CANC - 3490 OLYMPIA17117CommercialInterventionalNo1 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo7 EPHOS-B5501Non-CommercialInterventionalNo1 FAST-Forward10896Non-CommercialInterventionalNo83 FOAM Trial18588Non-CommercialInterventionalNo1 IMPORT HIGH2254Non-CommercialInterventionalNo111 LATTE6509Non-CommercialObservationalNo23 MAMMO-5016250Non-CommercialBothYes123 MANTA15689Non-CommercialInterventionalNo6 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo292 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo6 NCRN - 2787 / BravO niraparib vs physician's choice in HER2- BRCA BrCa15877CommercialInterventionalNo1 NCRN - 3233 Enzalutamide with Trastuzumab in HER2+ AR+ MBCa16492CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo6 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC 13595CommercialInterventionalNo1 NCRN559 HERBIO: ABP 980 vs trastuzumab in HER2+ early BC14623CommercialInterventionalNo5 PAKT16095Non-CommercialInterventionalNo4 POSNOC16069Non-CommercialInterventionalYes13 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)28 RAPPER1471Non-CommercialObservationalYes (LC)276 SEARCH1390Non-CommercialObservationalYes (LC)236 Data from Portfolio ODP – Cut off 21/08/15

5. Breast Tumour Group Open Studies Eastern Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo31 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo2 Chemo-NEAR10052Non-CommercialObservationalYes (LC)11 FAST-Forward10896Non-CommercialInterventionalNo447 IMPORT HIGH2254Non-CommercialInterventionalNo683 LATTE6509Non-CommercialObservationalNo28 LORIS16736Non-CommercialInterventionalNo1 MAMMO-5016250Non-CommercialBothYes37 MANTA15689Non-CommercialInterventionalNo7 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo6 NCRN - 2802 OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo1 NCRN - 3113 BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo5 NCRN186 ALTERNATIVE - Lapatinib + Traztuzumab + AI in 1st line ER+/HER2+ MBC 11343CommercialInterventionalNo1 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo2 PAKT16095Non-CommercialInterventionalNo3 POSEIDON18165Non-CommercialInterventionalNo5 POSNOC16069Non-CommercialInterventionalYes4 Prevention of Lymphoedema after Clearance by External Compression (PLACE) 9074Non-CommercialBothYes (LC)1 Proteins CTCF and BORIS as biomarkers in breast and prostate cancers5712Non-CommercialObservationalNo1,017 RADICAL11456Non-CommercialInterventionalNo13 RAPPER1471Non-CommercialObservationalYes (LC)662 SEARCH1390Non-CommercialObservationalYes (LC)12,153

6. Breast Tumour Group Open Studies Greater Manchester 1 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN ID Study TypeStudy Design Open to New Sites? Total Recruitment An exploratory breast lead interval study (EBLIS)15783Non-CommercialObservationalNo23 B-AHEAD3: Breast Activity and Healthy Eating After Diagnosis 318070Non-CommercialInterventionalNo2 Breast Cancer Risk Communication17977Non-CommercialObservationalNo38 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo43 BRRIDE 2 Breast Risk Reduction Intermittent Diet Evaluation18052Non-CommercialInterventionalNo27 CANC - 3699 - BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo1 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo3 CHAMPion8685Non-CommercialObservationalNo492 Digital breast tomosynthesis in screening younger higher risk women16312Non-CommercialInterventionalNo859 EPHOS-B5501Non-CommercialInterventionalNo60 FAKTION16319Non-CommercialInterventionalYes6 IMPORT HIGH2254Non-CommercialInterventionalNo69 LATTE6509Non-CommercialObservationalNo137 LORIS16736Non-CommercialInterventionalNo1 MAMMO-5016250Non-CommercialBothYes205

7. Breast Tumour Group Open Studies Greater Manchester 2 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo443 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo5 NCRN - 2802 OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo4 NCRN - 3216 BMN 673 in patients with metastatic breast cancer and a BRCA mutation 16486CommercialInterventionalNo2 NCRN - 3233 Enzalutamide with Trastuzumab in HER2+ AR+ MBCa16492CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo6 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC13595CommercialInterventionalNo1 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo1 OPPORTUNE11583Non-CommercialInterventionalNo43 POSNOC16069Non-CommercialInterventionalYes27 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)45 PROCAS – Lifestyle Breast Cancer Prevention Feasibility Study17480Non-CommercialInterventionalNo71 RADICAL11456Non-CommercialInterventionalNo2 RAPPER1471Non-CommercialObservationalYes (LC)715 SEARCH1390Non-CommercialObservationalYes (LC)234

8. Breast Tumour Group Open Studies Kent, Surrey and Sussex Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo10 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo5 EORTC 100858593Non-CommercialObservationalNo4 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo3 FAST-Forward10896Non-CommercialInterventionalNo250 IMPORT HIGH2254Non-CommercialInterventionalNo67 LATTE6509Non-CommercialObservationalNo37 MAMMO-5016250Non-CommercialBothYes76 MANTA15689Non-CommercialInterventionalNo17 NCRN - 2558 - Neoadjuvant Letrozole and GDC-0032 in ER+/HER2- Breast Cancer 16325CommercialInterventionalNo1 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo8 NCRN186 ALTERNATIVE - Lapatinib + Traztuzumab + AI in 1st line ER+/HER2+ MBC 11343CommercialInterventionalNo2 OPPORTUNE11583Non-CommercialInterventionalNo15 PAKT16095Non-CommercialInterventionalNo3 POSNOC16069Non-CommercialInterventionalYes9 RAPPER1471Non-CommercialObservationalYes (LC)337 SEARCH1390Non-CommercialObservationalYes (LC)15

9. Breast Tumour Group Open Studies North East and North Cumbria Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo21 Digital breast tomosynthesis in younger symptomatic women.9918Non-CommercialInterventionalYes89 EPHOS-B5501Non-CommercialInterventionalNo7 FAST-Forward10896Non-CommercialInterventionalNo30 IMPORT HIGH2254Non-CommercialInterventionalNo32 LATTE6509Non-CommercialObservationalNo38 MAMMO-5016250Non-CommercialBothYes41 MANTA15689Non-CommercialInterventionalNo4 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo5 NCRN - 3113 BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo2 POSNOC16069Non-CommercialInterventionalYes2 RADICAL11456Non-CommercialInterventionalNo5 RAPPER1471Non-CommercialObservationalYes (LC)50 SEARCH1390Non-CommercialObservationalYes (LC)108

10. Breast Tumour Group Open Studies North Thames Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo41 CANC - 3490 OLYMPIA17117CommercialInterventionalNo1 EPHOS-B5501Non-CommercialInterventionalNo6 FAST-Forward10896Non-CommercialInterventionalNo207 IMPORT HIGH2254Non-CommercialInterventionalNo194 LATTE6509Non-CommercialObservationalNo19 MAMMO-5016250Non-CommercialBothYes60 MANTA15689Non-CommercialInterventionalNo8 OPPORTUNE11583Non-CommercialInterventionalNo14 PAKT16095Non-CommercialInterventionalNo3 PICTURE BREAST Longitudinal17421Non-CommercialObservationalNo22 PICTURE BREAST XS (cross-sectional)16682Non-CommercialObservationalNo72 RAPPER1471Non-CommercialObservationalYes (LC)84 SEARCH1390Non-CommercialObservationalYes (LC)5,692 TARGIT-B Trial of radiotherapy in higher risk breast cancer patients14208Non-CommercialInterventionalYes66

11. Breast Tumour Group Open Studies North West Coast Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo226 CANC - 3699 - BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo1 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo4 CiPHER16444Non-CommercialInterventionalYes1 EPHOS-B5501Non-CommercialInterventionalNo9 FAST-Forward10896Non-CommercialInterventionalNo204 IMPORT HIGH2254Non-CommercialInterventionalNo229 LATTE6509Non-CommercialObservationalNo36 MAMMO-5016250Non-CommercialBothYes77 NCRN - 2787 / BravO niraparib vs physician's choice in HER2- BRCA BrCa15877CommercialInterventionalNo2 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC13595CommercialInterventionalNo2 POSNOC16069Non-CommercialInterventionalYes8 RAPPER1471Non-CommercialObservationalYes (LC)623 SEARCH1390Non-CommercialObservationalYes (LC)159

12. Breast Tumour Group Open Studies North West London Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment An exploratory breast lead interval study (EBLIS)15783Non-CommercialObservationalNo86 Breast Screening and Monitoring Study13803Non-CommercialObservationalNo1,238 Chemotherapy induced changes in [18F]ICMT1113225Non-CommercialObservationalNo17 FAST-Forward10896Non-CommercialInterventionalNo86 IMPORT HIGH2254Non-CommercialInterventionalNo27 MAMMO-5016250Non-CommercialBothYes52 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo3 NCRN - 2802 OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo1 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo9 PAKT16095Non-CommercialInterventionalNo1 POPPET16020Non-CommercialObservationalNo3 RADICAL11456Non-CommercialInterventionalNo10 RAPPER1471Non-CommercialObservationalYes (LC)56 SEARCH1390Non-CommercialObservationalYes (LC)17 TARGIT-B Trial of radiotherapy in higher risk breast cancer patients14208Non-CommercialInterventionalYes5 VERB Study13222Non-CommercialInterventionalNo5

13. Breast Tumour Group Open Studies South London 1 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo146 CANC - 3490 OLYMPIA17117CommercialInterventionalNo10 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo5 CANC - 3837 A Study of Ruxolitinib in advanced HER219078CommercialInterventionalNo1 Chemo-NEAR10052Non-CommercialObservationalYes (LC)122 Digital breast tomosynthesis in screening younger higher risk women16312Non-CommercialInterventionalNo266 EPHOS-B5501Non-CommercialInterventionalNo27 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo104 FAST-Forward10896Non-CommercialInterventionalNo210 Functional Assessment of Breast Cancer in Bone (FABB study)13473Non-CommercialObservationalNo18 Immunopathogenesis and Molecular Biology in Breast Cancer Subtypes15152Non-CommercialObservationalYes (LC)378 IMPORT HIGH2254Non-CommercialInterventionalNo233 LATTE6509Non-CommercialObservationalNo9 LORIS16736Non-CommercialInterventionalNo1 Magnetic Sentinel Node and Occult Lesion Localisation (MagSNOLL)14979Non-CommercialInterventionalYes57 MAMMO-5016250Non-CommercialBothYes17 MANTA15689Non-CommercialInterventionalNo7 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo153 NCRN - 2517 Cerenkov Luminescence Imaging in breast cancer16259CommercialInterventionalNo20 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo6

14. Breast Tumour Group Open Studies South London 2 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment NCRN - 2678 / FINESSE - lucitanib in ER+ metastatic BrCa15473CommercialInterventionalNo6 NCRN - 2787 / BravO niraparib vs physician's choice in HER2- BRCA BrCa15877CommercialInterventionalNo8 NCRN - 3113 BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo19 NCRN - 3319 non-steroidal aromatase inhibitors + LY2835219 in breast cancer 17753CommercialInterventionalNo2 NCRN186 ALTERNATIVE - Lapatinib + Traztuzumab + AI in 1st line ER+/HER2+ MBC 11343CommercialInterventionalNo1 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo6 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC 13595CommercialInterventionalNo5 OPPORTUNE11583Non-CommercialInterventionalNo39 PAKT16095Non-CommercialInterventionalNo10 PALLET17716Non-CommercialInterventionalYes5 Phase I study of AT13148, a novel AGC kinase inhibitor11846Non-CommercialInterventionalNo40 POSNOC16069Non-CommercialInterventionalYes1 PREHEAT Trial - local heat preconditioning and wound healing18442Non-CommercialInterventionalNo29 Prevention of Lymphoedema after Clearance by External Compression (PLACE) 9074Non-CommercialBothYes (LC)9 RAPPER1471Non-CommercialObservationalYes (LC)1,109 SEARCH1390Non-CommercialObservationalYes (LC)71

15. Breast Tumour Group Open Studies South West Peninsula Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo14 CANC - 3699 - BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo7 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo10 CANC - 3837 A Study of Ruxolitinib in advanced HER219078CommercialInterventionalNo2 Chemo-NEAR10052Non-CommercialObservationalYes (LC)34 Digital breast tomosynthesis in younger symptomatic women.9918Non-CommercialInterventionalYes60 EPHOS-B5501Non-CommercialInterventionalNo19 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo10 FAST-Forward10896Non-CommercialInterventionalNo617 FURVA, Version 1.018232Non-CommercialInterventionalNo1 IMPORT HIGH2254Non-CommercialInterventionalYes77 LATTE6509Non-CommercialObservationalNo54 LORIS16736Non-CommercialInterventionalNo1 MAMMO-5016250Non-CommercialBothYes26 MANTA15689Non-CommercialInterventionalNo9 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo20 NCRN - 2802 OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer16109CommercialInterventionalNo1 NCRN - 2973 MONALEESA-2 LEE011 + letrozole in ER+ HER2- advanced BC16241CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo12 OPPORTUNE11583Non-CommercialInterventionalNo23 PAKT16095Non-CommercialInterventionalNo6 PALLET17716Non-CommercialInterventionalYes5 POSNOC16069Non-CommercialInterventionalYes2 RAPPER1471Non-CommercialObservationalYes (LC)232 SEARCH1390Non-CommercialObservationalYes (LC)272

16. Breast Tumour Group Open Studies Thames Valley and South Midlands Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847 Non- Commercial ObservationalNo36 CANC - 3699 - BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo2 FAST-Forward10896 Non- Commercial InterventionalNo104 IMPORT HIGH2254 Non- Commercial InterventionalNo42 MAMMO-5016250 Non- Commercial BothYes2 NCRN - 3113 BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo4 POSNOC16069 Non- Commercial InterventionalYes,4 RAPPER1471 Non- Commercial ObservationalYes (LC)26 SEARCH1390 Non- Commercial ObservationalYes (LC)119

17. Breast Tumour Group Open Studies Wessex Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes4 Body composition & chemo response & toxicity in early breast cancer16944Non-CommercialObservationalNo32 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo43 CANC - 3490 OLYMPIA17117CommercialInterventionalNo1 CANC - 3699 - BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo1 Chemo-NEAR10052Non-CommercialObservationalYes (LC)33 Digital breast tomosynthesis in younger symptomatic women.9918Non-CommercialInterventionalYescountry16 EPHOS-B5501Non-CommercialInterventionalNo150 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo4 FAST-Forward10896Non-CommercialInterventionalNo181 IMPORT HIGH2254Non-CommercialInterventionalNo94 KYN: Alcohol and breast cancer prevention18494Non-CommercialObservationalNo208 LATTE6509Non-CommercialObservationalNo31 MAMMO-5016250Non-CommercialBothYes37 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo203 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo2 NCRN - 3113 BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo2 PAKT16095Non-CommercialInterventionalNo1 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)25 RAPPER1471Non-CommercialObservationalYes (LC)27 SEARCH1390Non-CommercialObservationalYes (LC)234 The BeGIN study: Investigating Outcomes from Breast Cancer18500Non-CommercialObservationalNo2 Understanding immunity in lymph nodes. V 111947Non-CommercialObservationalNo42

18. Breast Tumour Group Open Studies West Midlands Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo22 CANC - 3490 OLYMPIA17117CommercialInterventionalNo1 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo4 EPHOS-B5501Non-CommercialInterventionalNo37 FAST-Forward10896Non-CommercialInterventionalNo933 IMPORT HIGH2254Non-CommercialInterventionalNo221 LATTE6509Non-CommercialObservationalNo58 LORIS16736Non-CommercialInterventionalNo3 MAMMO-5016250Non-CommercialBothYes212 MANTA15689Non-CommercialInterventionalNo5 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo50 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo26 NCRN - 2802 OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo4 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo3 PAKT16095Non-CommercialInterventionalNo1 POSNOC16069Non-CommercialInterventionalYes8 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)5 RADICAL11456Non-CommercialInterventionalNo1 RAPPER1471Non-CommercialObservationalYes (LC)725 SEARCH1390Non-CommercialObservationalYes (LC)518

19. Breast Tumour Group Open Studies West of England Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo99 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo3 CONCEPT (Breast Cancer)17993Non-CommercialInterventionalNo4 EORTC 100858593Non-CommercialObservationalNo1 FAST-Forward10896Non-CommercialInterventionalNo162 FURVA, Version 1.018232Non-CommercialInterventionalYes,3 IMPORT HIGH2254Non-CommercialInterventionalNo269 LATTE6509Non-CommercialObservationalNo35 MAMMO-5016250Non-CommercialBothYes,96 MANTA15689Non-CommercialInterventionalNo3 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo1 NCRN - 3113 BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo4 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo2 POSNOC16069Non-CommercialInterventionalYes,6 RAPPER1471Non-CommercialObservationalYes (LC)121 SEARCH1390Non-CommercialObservationalYes (LC)188 TARGIT-B Trial of radiotherapy in higher risk breast cancer patients14208Non-CommercialInterventionalYes1

20. Breast Tumour Group Open Studies Yorkshire and Humber Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo633 CANC - 3490 OLYMPIA17117CommercialInterventionalNo1 CANC - 3699 - BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo2 CANC - 3831 MBC - disease registry study18055CommercialObservationalNo5 DETECT7266Non-CommercialObservationalNo398 EPHOS-B5501Non-CommercialInterventionalNo45 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo12 FAST-Forward10896Non-CommercialInterventionalNo110 IMPORT HIGH2254Non-CommercialInterventionalNo219 LATTE6509Non-CommercialObservationalNo265 Lymphocyte phenotype and cytokine production in patients with fatigue.15893Non-CommercialObservationalNo65 MAMMO-5016250Non-CommercialBothYes101 MANTA15689Non-CommercialInterventionalNo4 NCRN - 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo17 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo13 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo7 OPPORTUNE11583Non-CommercialInterventionalNo5 PAKT16095Non-CommercialInterventionalNo1 POSNOC16069Non-CommercialInterventionalYes23 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)3 RAPPER1471Non-CommercialObservationalYes (LC)222 SEARCH1390Non-CommercialObservationalYes (LC)131

21. Breast Tumour Group South West Peninsula Sites Data from Portfolio ODP – Cut off 21/08/15

22. Breast Tumour Group South West Peninsula Sites Data from Portfolio ODP – Cut off 21/08/15 Trust 2014/20152015/2016 Commercial Non- Commercial Commercial Non- Commercial Northern Devon Healthcare NHS Trust01203 Plymouth Hospitals NHS Trust43322 Royal Cornwall Hospitals NHS Trust23481722 Royal Devon and Exeter NHS Foundation Trust53806 South Devon Healthcare NHS Foundation Trust043012 Taunton and Somerset NHS Foundation Trust572123 Yeovil District Hospital NHS Foundation Trust14106

23. Breast Tumour Group South West Peninsula Open Studies 1 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrust Investigator Name End DateTargetRecruitment 2015/2016 Recruitment RTT AFFECT6140Non-CommercialPlymouth Hospitals NHS Trust Brewer, Dr Carole 30-Sep-16 2010-75 AFFECT6140Non-Commercial South Devon Healthcare NHS Foundation Trust Brewer, Dr Carole 30-Sep-16 000 AKT inhibitor in breast cancer (STAKT study) 14498Non-CommercialPlymouth Hospitals NHS TrustKelly, Dr Steve 14-Jul-16 32124 BOUDICA17941CommercialPlymouth Hospitals NHS TrustKelly, Dr Steve 01-Dec-16 400-12 BOUDICA17941Commercial Royal Cornwall Hospitals NHS Trust Thomson, Dr Alastair 31-Dec-16 66680 BOUDICA17941Commercial Royal Devon and Exeter NHS Foundation Trust Scatchard, Dr Kate 31-Dec-16 500-11 BOUDICA17941Commercial Taunton and Somerset NHS Foundation Trust Barthakur, Urmila 00 CANC - 3831 MBC - disease registry study Esther 18055CommercialPlymouth Hospitals NHS TrustDubey, Dr Sid 31-Mar-18 1622 CANC - 3831 MBC - disease registry study Esther 18055Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 27-Feb-18 158839 Chemo-NEAR10052Non-Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 31-Mar-15 10295166 Chemo-NEAR10052Non-Commercial Taunton and Somerset NHS Foundation Trust Varughese, Dr Mohini 01-Dec-15 255186 CO-OPS13796Non-CommercialPlymouth Hospitals NHS TrustSteel, Mr Jim 31-Dec-14 000 Digital breast tomosynthesis in younger symptomatic women. 9918Non-CommercialPlymouth Hospitals NHS TrustSteel, Mr Jim 30-Nov-15 5060031 EPHOS-B5501Non-Commercial Royal Devon and Exeter NHS Foundation Trust Hong, Dr Anne 31-Jul-15 21160-24 EPHOS-B5501Non-Commercial Yeovil District Hospital NHS Foundation Trust Sparrow, Dr Geoff 30-Sep-15 510-76

24. Breast Tumour Group South West Peninsula Open Studies 2 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrustInvestigator NameEnd DateTargetRecruitment 2015/2016 Recruitment RTT Evaluating outcomes of immediate breast reconstruction (POBRAD-M) 16816Non-Commercial Royal Cornwall Hospitals NHS Trust Brown, Mr Iain 11-Feb-16 40108-23 FURVA18232Non-Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 01-Dec-18 31130 FURVA18232Non-Commercial Royal Devon and Exeter NHS Foundation Trust Hong, Dr Anne 01-May-17 600-7 IMPORT HIGH2254Non-Commercial Plymouth Hospitals NHS Trust Kelly, Dr Steve 01-Jun-15 2538048 IMPORT HIGH2254Non-Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 24-Mar-25 233146 IMPORT HIGH2254Non-Commercial South Devon Healthcare NHS Foundation Trust Bliss, Dr Peter 30-Apr-15 28 2-11 LORIS16736Non-Commercial Royal Cornwall Hospitals NHS Trust Barta, Dr Miklos 31-Aug-16 300-40 LORIS16736Non-Commercial Royal Devon and Exeter NHS Foundation Trust Ferguson, Mr Douglas 01-Aug-31 61011 MAMMO-5016250Non-Commercial Royal Cornwall Hospitals NHS Trust Barta, Dr Miklos 22-Apr-20 17716 4 MAMMO-5016250Non-Commercial Royal Devon and Exeter NHS Foundation Trust Ferguson, Mr Douglas 30-Jun-17 20333 MAMMO-5016250Non-Commercial South Devon Healthcare NHS Foundation Trust Donnelly, Mr Peter 30-Jun-17 1451311-15 MAMMO-5016250Non-Commercial Taunton and Somerset NHS Foundation Trust Thorne, Miss Amanda 30-Jun-18 10143114 MAMMO-5016250Non-Commercial Yeovil District Hospital NHS Foundation Trust Ansari, Mr Bijan 30-Jun-18 2010519 MANTA15689Non-Commercial Plymouth Hospitals NHS Trust Dubey, Dr Sid 03-Apr-16 2102431 MANTA15689Non-Commercial Yeovil District Hospital NHS Foundation Trust Sparrow, Dr Geoff 27-Apr-18 510-15

25. Breast Tumour Group South West Peninsula Open Studies 3 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrust Investigator Name End DateTargetRecruitment 2015/2016 Recruitment RTT NCRN - 2844 Enzalutamide in Combination with Exemestane in Advanced Breast Cancer 15943Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 28-Mar-161060-7 NCRN384 - KATHERINE13395Commercial Northern Devon Healthcare NHS Trust Scatchard, Dr Kate 31-Mar-1633022 NCRN384 - KATHERINE13395Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 31-Mar-16590102 NCRN522 PEGGY: PACLITAXEL + GDC-0941 vs PACLITAXEL + PLACEBO IN METASTATIC BREAST CANCER 13693Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 31-Mar-16530-18 OPPORTUNE11583 Non- Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 01-Apr-1510232108 PAKT Study16095 Non- Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 25-Apr-1634170 PAKT Study16095 Non- Commercial Yeovil District Hospital NHS Foundation Trust Barthakur, Urmila 28-Feb-163211 PALLET17716 Non- Commercial Plymouth Hospitals NHS Trust Panwar, Dr Udaiveer 03-Sep-1821139 PALLET17716 Non- Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 01-Sep-16352135 Persephone4078 Non- Commercial Northern Devon Healthcare NHS Trust Hwang, Dr David 31-Jul-1530141-54 Persephone4078 Non- Commercial South Devon Healthcare NHS Foundation Trust Goodman, Dr Andrew 30-Jun-1616402161 Persephone4078 Non- Commercial Taunton and Somerset NHS Foundation Trust Varughese, Dr Mohini 30-Jun-1640287-30 Persephone4078 Non- Commercial Yeovil District Hospital NHS Foundation Trust Sparrow, Dr Geoff 30-Jun-1610293201

26. Breast Tumour Group South West Peninsula Open Studies 4 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrustInvestigator NameEnd DateTargetRecruitment 2015/2016 Recruitment RTT POSNOC16069Non-CommercialRoyal Cornwall Hospitals NHS TrustAhmad, Mr Sheikh31-Mar-1892111216 POSNOC16069Non-Commercial Yeovil District Hospital NHS Foundation Trust Osborne, Ms Caroline31-Mar-1810113 RAPPER1471Non-CommercialPlymouth Hospitals NHS TrustNatale, Mr Salvatore31-Aug-181518270 RAPPER1471Non-Commercial Royal Devon and Exeter NHS Foundation Trust Srinivasan, Dr Rajaguru31-Aug-1840626111 RAPPER1471Non-Commercial South Devon Healthcare NHS Foundation Trust Lydon, Dr Anna31-Aug-1831800209 RAPPER1471Non-Commercial Taunton and Somerset NHS Foundation Trust Varughese, Dr Mohini31-Aug-1810736680 SEARCH1390Non-Commercial Northern Devon Healthcare NHS Trust Scatchard, Dr Kate30-Sep-162641285 SEARCH1390Non-Commercial Royal Devon and Exeter NHS Foundation Trust Investigator, No Local30-Sep-160971 SEARCH1390Non-Commercial Taunton and Somerset NHS Foundation Trust Cattell, Dr Emma30-Sep-1611899740 SEARCH1390Non-Commercial Yeovil District Hospital NHS Foundation Trust Barlow, Dr Clare31-Dec-2020510222 UNIRAD17765Non-CommercialRoyal Cornwall Hospitals NHS TrustWheatley, Dr Duncan01-Dec-171200-3

27. Division 1 Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk 01872 258312duncan.wheatley@rcht.cornwall.nhs.uk Wendy Cook, Research Delivery Manager wcook1@nhs.net 01392 406995 wcook1@nhs.net Ann Courtman, Administrator ann.courtman@nhs.net ann.courtman@nhs.net 01392 406966 27